EMEA-000430-PIP01-08-M11

Key facts

Invented name
Xarelto
Active substance
rivaroxaban
Therapeutic area
Cardiovascular diseases
Decision number
P/0126/2019
PIP number
EMEA-000430-PIP01-08-M11
Pharmaceutical form(s)
  • Oral suspension
  • Film-coated tablet
Condition(s) / indication(s)
  • Prevention of thromboembolic events
  • Treatment of thromboembolic events
Route(s) of administration
Oral use
Contact for public enquiries
Bayer Pharma AG

Tel. +49 3046 815333
E-mail: pediatrics.medical-affairs-europe@bayer.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating